Collaboration on Novel Protein
Ivrea/Paris - Nautilus Biotech SA (France) and Creabilis Therapeutics SRL (Italy) recently signed a collaboration agreement for the identification and development of an improved variant of CT500, a non-antibody protein selected by Creabilis Therapeutics, with antagonist activity against HMGB1. HMGB1 is a DNA-binding chemo-cytokine that due to its key - and in some cases causative - role in several pathological conditions has become a relevant drug target in recent years. The new anti-HMGB1-variant protein, object of the agreement, is expected to have potential applications in various acute and chronic clinical indications such as autoimmune diseases, infective diseases, sepsis, tumours, cardiovascular and also neurologic and amyloid pathologies.
Nautilus' proprietary technology for protein evolution based on systematic mutagenesis, which is already successfully applied to a number of well-known thera-peutic proteins, will be used to improve the pharmacodynamic profile of CT500. The terms of the agreement have not been disclosed.
Manuel Vega, CEO of Nautilus Biotech comments: “So far our technology has been applied to marketed proteins, such as
IFN- and IFN- , to improve them by single point aminoacid substitution to create new products with highly competitive PK/PD characteristics compared to the marketed counterparts. This agreement allows us to apply the same methodology to a novel protein at a very early stage of development. It is a good demonstration of the flexibility of our approach that can be used to improve lead proteins right after the discovery phase.”
“We are most confident”, said Creabilis Therapeutic's CEO Silvano Fumero, “that Nautilus' technology will enable us to obtain an improved candidate drug with higher and competitive pharmacological and clinical potential.”